The bacteriophage market is capturing a valuation of USD 45.07 million in 2023 and is predicted to reach USD 68 million by 2033. The market is likely to register a CAGR of 4.2% during the forecast period.
The demand for bacteriophages is increasing due to their dietary supplement use. Its adoption reduces the risk of incidence of food born infections. These dietary supplements contain a specific combination of bacteriophages that attacks particular organisms in the gut.
Phage therapeutics can be used to treat and prevent antibiotic resistance infections, urinary tract infections, dysentery, and others. The rising demand for personalized medicine and advanced phage therapy research is fueling the market growth.
The rising bacterial infection due to the aging population, climate change, and global travel are increasing the adoption of bacteriophage. Public and private companies' rising investment in the phage therapy sector enhances market opportunities. Through research and development activities, they are carryout better phage-based treatments.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 4.2% |
| Market Valuation (2023) | USD 45.07 million |
| Market Valuation (2033) | USD 68 million |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Several factors decline the growth of the market are:
The high cost of bacteriophage treatment is a leading factor limiting the market growth. Due to the high cost of therapy, several healthcare facilities, such as small hospitals & clinics, cannot afford the treatment. In underdeveloped areas, the lack of facilities and treatment also leads to a decline in the demand for bacteriophage.
Low and middle-income countries generate more revenue from antibiotics as compared to bacteriophage. They require cheaper and show immediate results are slow down the market growth in these countries.
The changing consumer preferences for alternative treatment, lack of new innovative treatments, and economic downfall are restraining the market growth.
Growing research and development of drugs and therapies for infectious diseases is expected to create immense market opportunities. Rising interest in developing drugs such as infectious diseases and immunological disorders boosts the market.
For instance, in June 2020, Microgen opened a Biological Research Center to study bacteriophages. The main purpose of this center is to improve the treatment and prevention of drugs being an alternative to antibiotics.
According to research by the World Health Organization, antibiotic-resistant infections could kill about 10 million people yearly by 2050. There is a huge unmet need in patients with bacterial infections. These are mostly very difficult to treat with traditional antibiotic therapy.
For instance, In October 2021, Intralytix, Inc. received clearance from the United States Food and Drug Administration for an Investigational New Drug (IND) application for its product ShigActive.
According to Future Market Insights, the overall bacteriophage sales were valued at around USD 43.2 million in 2022.
The human gut is easily prone to attack by bacteriophages. As bacteriophages are bacteria eaters, they can easily affect the gut microbiota population and, in turn, influence gene expression patterns in microbes.
The consumption of phage probiotics promotes good bacteria over bad bacteria and maintains a good balance. It promotes a healthy lifestyle among individuals. For instance, In June 2021, Life Extension launched a new formula for supporting bowel regularity, FLORASSIST Daily Bowel Regularity.
The probiotic strain has been shown to maintain bowel regularity and defend against occasional constipation. A slew of such developments by key players is expected to boost the market. The rising prevalence of antibiotic resistance and limited discoveries for new antibiotics propel the market growth.
It has shifted the focus of healthcare professionals in developed countries toward research and development. It is projected to improve the demand in the bacteriophage market, replacing traditional probiotics.
For instance, in January 2020, Life Extension developed a novel approach for supporting healthy liver, FLORASSIST Liver Restore. This daily, synbiotic proprietary blend combines clinically-studied PRObiotic bacteria with PRE-biotic that helps those strains thrive in the gut.
Based on product type, the phage probiotics segment is securing a share of 95.39% in the global market. The growth of this product is associated with its ability to improve gut flora diversity and promote the growth of good bacteria. The rising demand for natural alternatives and growing awareness is increasing the adoption of phage probiotics.
Preference for Non-invasive Treatment to Increase the Demand for Oral Route of Administration in the Market
Oral route of administration benefits the most as they have more than 96% share in revenue and is expected to record a CAGR of 4.3% in the forecast period. It is a highly preferred route of administration since it is self-administrable, non-invasive, and cost-effective.
Demand for Bacteriophage Formulations in Gastroenterology to Increase
Based on application, the gastroenterology segment is anticipated to capture a share of 94% during the forecast period. Bacteriophages are used as dietary supplements to improve gut health.
Bacteriophages are still not approved by United States FDA as a treatment option for many antibiotic-resistant infections in many regions.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
| Countries | Projected Share |
|---|---|
| United States | 26.3% |
| Germany | 4.4% |
| Japan | 3.1% |
| Australia | 5.0% |
| China | 6.80% |
| India | 5.40% |
| United Kingdom | 3.20% |
The United States is estimated to dominate the global market by capturing a share of 26.3% during the forecast period. The bacteriophage is an entry-level state in the country. The rising prevalence of antibiotic resistance and increasing demand for an alternative to antibiotics in the country.
Several institutions are investing in research and development activities to improve phage therapy. Various companies in the United States are treating bacterial infections in animals, humans, agricultural use, and food safety. The key companies in the United States bacteriophage market are PhagePro, AmpliPhi Biosciences, Intralytix, and Adaptive Phage Therapeutics.
Germany is significantly growing the global market by registering a share of 4.4% during the forecast period. The increasing demand for treating infectious bacteria is growing German market. The country is growing with favorable regulatory policies and less stringent rules for approving bacteriophage formulations.
Institutes are developing products such as drugs and medicine for several industries. They adopt new treatments and therapies through their research and developments, surging the market size. The rising clinical settings for bacteriophage are estimated to fuel the market size in the country.
Australia to Emerge as a Lucrative Market in Oceania
Sales of bacteriophage in Australia are projected to increase by 5% during the forecast period. The country is attributed to the rising wave of advancements in phage therapy strategies in Oceania.
Australia is one of the significant countries with market potential growth. The increasing patient demand for antibiotic infections is rising the medical products in the country. The rising various institutional and academic research are performing their role to enhance the market size.
India Bacteriophage Market to Spearhead the Growth in South Asia
During the forecast period, India is anticipated to secure a share of 5.40% in the global market. Demand for bacteriophage is witnessing a rapid increase in antibacterial-resistant infections in India.
Key companies in India are collaborating and extending their partnerships with pre-existing giants to expand their product portfolio. It is expected to facilitate growth in the market. The rapidly growing clinics and hospitals in the use of bacteriophage fueling the Indian market.
The manufacturers are expanding the global market in several ways are:
Leading bacteriophage manufacturers are focusing on geographical expansion to increase their revenue & expand their footprint. These players are innovating to improve products that desire end-users requirements. These essential players are adopting various marketing strategies to upsurge the market to another height.
The marketing methodologies are strategic collaborations, acquisitions, expansion, product launches, agreements, and research sponsorship. The key strategies adopted by manufacturers to increase product sales in different geographies.
Other Prominent Players in the Global Market are:
Recent Developments in the Market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million for Value |
| Key Countries Covered | United States, United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Product Type, Application, Route of Administration, Distribution Channel, Region |
| Key Companies Profiled | Life extension; Arthur Andrew Medical; Deerland Probiotics & Enzymes Inc.; BioChimpharm; Micreos Human Health; Designs for Health; Accelerated Health Systems LLC; The biostation; Microgen; IntraLytix Inc. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The gas steam segment leads and could exhibit a 2.5% CAGR through 2033.
The overall industry value could reach almost USD 68 million by 2033.
The global demand for bacteriophage is expected to rise at merely 4.2% CAGR through 2033.
The United States market held 26.3% market share in 2022.
The phage probiotics segment is highly popular with 95.39% market share in 2022.
| Market Size (2022) | USD 20.2 Billion |
|---|---|
| Projected Market Value (2032) | USD 35.1 Billion |
| Market CAGR (2022 to 2032) | 5.7% |
| Estimated Market Value (2022) | USD 3.7 Billion |
|---|---|
| Projected Market Value (2032) | USD 10.7 Billion |
| Value-based CAGR (2022 to 2032) | 11.3% |
Explore Life Science & Biotechnology Insights
View Reports
Bacteriophage Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
